Drug Trial Radar · NCT07815067
A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Sep 7, 2026
Primary completion
Jun 12, 2028
Study completion Jun 12, 2028
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Sep 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to test how taking zenagamtide tablets with different meal/water variations affects how much zenagamtide enters the bloodstream in people who have overweight or obesity. All participants will get zenagamtide.
Conditions
- Overweight
- Obesity
Interventions
Zenagamtide injectionDrug
Zenagamtide will be administered to one of the body parts: thigh, abdomen or upper arm
Zenagamtide tabletDrug
Zenagamtide tablet will be taken in the morning in fasted state.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC, zenagamtide, steady state (ss): area under the zenagamtide plasma concentration-time curve during a dosing interval at steady stateTime frame: From 0 (pre-dose) up to Day 196 and Day 224
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Charité - Campus Charité Mitte - Charité Research Organisation GmbH
Berlin, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.